A population-based comparison of second primary cancers in Germany and Sweden between 1997 and 2006: clinical implications and etiologic aspects

Hao Liu, Kari Hemminki, Jan Sundquist, Bernd Holleczek, Alexander Katalinic, Katharina Emrich, Lina Jansen, Hermann Brenner & the GEKID Cancer Survival Working Group

1Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
2Center for Primary Health Care Research, Lund University, Malmö, Sweden
3Stanford Prevention Research Center, Stanford University School of Medicine, Palo Alto, California
4Saarland Cancer Registry, Saarbrücken, Germany
5Cancer Registry of Schleswig-Holstein, Institute of Cancer Epidemiology, University of Lübeck, Lübeck, Germany
6Cancer Registry of Rhineland-Palatinate, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany
7Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany

Keywords
Clinical implications, etiologic aspects, population-based comparison, second primary cancer

Abstract
Second primary cancer (SPC) has become an increasing concern in cancer survivorship. Patterns of SPCs in different populations may offer clinical implications and research priorities into SPCs. This study is devoted to compare the occurrences and rank correlations of SPCs between Germany and Sweden. Patients diagnosed with 10 common first primaries between 1997 and 2006 from the Swedish Family-Cancer Database and 10 German cancer registries were included in this population-based study. Spearman’s rank correlation coefficients were used to evaluate the strength of the relationship of SPCs between the German and Swedish datasets. Spearman’s rank correlation coefficients suggested a strong positive correlation between the German and Swedish datasets based on the ranks of thirty possible SPCs after all selected first cancers. This was also true when we compared the rankings and proportions of the five most common SPCs after site-specific first primaries between the two populations. For kidney cancer, non-Hodgkin’s lymphoma, and leukemia the components of the five most common SPCs was exactly the same. Also, the ranking and the proportions for the three most common SPCs (i.e., colorectal, bladder, and lung cancers) after prostate cancer were identical in the two populations, as were those after most other primary cancers. The strikingly consistent patterns of SPCs in the two populations provide excellent opportunities for joint studies and they also suggest that many underlying reasons for SPC may have universal and tangible causes that await mechanistic dissection.

Introduction
Second primary cancer (SPC) is one of the major prognostic factors among cancer survivors and it is estimated to be the sixth most common form of malignancy in the world [1]. Besides this general sense of priority, there should be a special emphasis on SPC research for various reasons, including the possibility of reducing risk of SPC through control of the relevant environmental, behavioral, and genetic factors, once these have been identified [2, 3]. Study of SPC will be rewarding if the scope and the strategies are properly set [4]. SPCs can
be grouped according to major identified etiologies, such as syndromic, treatment related, and shared exposure related [3]. Carcinogenesis of SPC is a complex process [2, 5], which may be caused by interactions between treatment for the first cancer, the genetic predisposition, as well as environmental and behavioral factors. Nielsen and colleagues found that heterogeneity in the risk of SPC was substantial across cancer types, pointing out the need to consider the pairs of first and second cancers rather than the overall risk [6]. Monitoring of the associations of particular first and SPCs in different populations may reveal novel carcinogenic pathways relevant to SPC, which may result in clinical practice improvement.

Many multicenter studies on SPCs have been conducted but the concordance in the occurrence of SPCs between various centers has rarely been reported. Obviously, the incidence of any primary cancers is related to the incidence of SPCs [7]. The present study is devoted to the comparison of the occurrence and ranking of specific SPC after 10 common first primaries between Germany and Sweden by using population-based cancer registries. Even though the overall cancer incidence is not very different between Sweden and the German cancer registries, rates of individual cancers differ, most notably for high rates in lung- and smoking-related cancers in German men, high prostate cancer rates in Swedish men, and somewhat higher colorectal cancer (CRC) rates among German men and women (Cancer Incidence in Five Continents IX, www.iarc.fr).

**Patients and Methods**

The present study used the data from two sources. One is the Swedish Family-Cancer Database which includes data on 12.1 million individuals in the latest update of the year 2008, and over 1.1 million cancer patients, retrieved from the Swedish Cancer Registry (1958–2008) [8]. The other source is the pooled dataset from 11 German cancer registries including data on 1.1 million cancer patients diagnosed between 1997 and 2006, covering a population of 33 million people [9]. The present study included 10 of these Germany cancer registries. For comparisons, the present study thus included only the cancer patients diagnosed during 1997–2006 from the two datasets. An ad hoc study of the diagnostic accuracy of second cancers in the Swedish Cancer Registry indicated that 98% were correctly classified [10], and the German cancer registries strictly followed the multiple primary coding rules of the International Agency for Research on Cancer (IARC). In the Swedish Cancer Registry, the basic coding of tumor site has been performed according to ICD-O/2 (1993–2004) and ICD-O/3 (2005-w) and the different classifications are translated to ICD-7 to enable longer trends (codes: 140-197, 200-209). In the German dataset, tumors were identified based on ICD-O/3 and later converted into ICD-10 (codes: C00-C75, C81-C96). The case numbers of the 10 common first primary cancers for the German and Swedish datasets are shown in Table 1. The SPCs were grouped into thirty major types in present study.

Spearman’s rank correlation coefficients were used to test the strength of the relationship of the ranks of thirty possible SPCs after site-specific first primaries between the German and Swedish datasets. All the analyses were carried out by using SAS software version 9.2. The study was approved by the local ethics committees and the recommendations of Declaration of Helsinki had been followed.

**Results**

Table 2 provides a summary of the five most common SPCs following 10 common first cancers in Germany and Sweden. The five leading SPCs after kidney cancer were identical between the two datasets, including prostate, colorectal, urinary bladder, lung, and breast cancers. For non-Hodgkin’s lymphoma (NHL) and leukemia, the same order of the five SPCs was also observed in the two datasets. In addition, the three most common SPCs after prostate cancer, ranked in descending prevalence, were CRC (20.9% in Germany vs. 23.7% in Sweden), bladder cancer (20.0% vs. 17.8%), and lung cancer (14.3% vs. 12.3%) (Table 2). For the remaining first cancers, four of the five leading SPCs were identical in the two populations (Table 2). For instance, the four SPCs after CRC were prostate, lung, breast, and kidney cancers. For lung cancer, the SPCs were the tumors of prostate, colorectum, urinary bladder, and upper aerodigestive tract. For breast cancer, the SPCs were colorectal, endometrial, lung, and

| Table 1. Case numbers of selected 10 first cancers in Germany and Sweden (1997–2006). |
|---------------------------------------------------------------|
| **First cancer sites** | **Germany** | **Sweden** |
|-----------------------|-------------|------------|
| Colorectum            | 149,038     | 38,789     |
| Lung                  | 98,856      | 24,953     |
| Breast                | 149,471     | 51,691     |
| Endometrium           | 28,215      | 10,373     |
| Prostate              | 126,928     | 66,057     |
| Kidney                | 35,900      | 7545       |
| Urinary bladder       | 41,274      | 15,963     |
| Melanoma              | 33,194      | 14,703     |
| NHL                   | 29,034      | 11,592     |
| Leukemia              | 20,058      | 10,504     |

NHL, non-Hodgkin’s lymphoma.
Table 2. Occurrence of the five most common SPCs and rank correlations of SPCs after 10 common first cancers between Germany and Sweden (1997–2006).

| First cancers | Second cancers | Germany | Sweden | Germany vs. | Sweden |
|---------------|---------------|---------|--------|-------------|--------|
|               |               | $N$     | %      |             |        |
| Colorectum    | Prostate      | 1050    | 20.1   | Prostate    | 584    | 27.2 |
|               | Lung          | 596     | 11.4   | Breast      | 247    | 11.5 |
|               | Breast        | 524     | 10.0   | Lung        | 187    | 8.7  |
|               | Kidney        | 444     | 8.5    | Bladder     | 182    | 8.5  |
|               | Stomach       | 335     | 6.4    | Kidney      | 98     | 4.6  |
| Lung          | Prostate      | 310     | 15.9   | Prostate    | 116    | 21.0 |
|               | Colorectum    | 256     | 13.1   | Colorectum  | 75     | 13.6 |
|               | UADT          | 249     | 12.8   | Breast      | 61     | 11.1 |
|               | Bladder       | 163     | 8.4    | Bladder     | 53     | 9.6  |
|               | Kidney        | 147     | 7.6    | UADT        | 28     | 5.1  |
| Breast        | Colorectum    | 674     | 19.8   | Colorectum  | 392    | 19.0 |
|               | Endometrium   | 490     | 14.4   | Endometrium | 269    | 13.0 |
|               | Lung          | 296     | 8.7    | Lung        | 241    | 11.7 |
|               | Ovary         | 243     | 7.1    | Ovary       | 130    | 6.3  |
|               | Kidney        | 235     | 6.9    | Melanoma    | 129    | 6.2  |
| Endometrium   | Breast        | 391     | 27.7   | Breast      | 215    | 28.2 |
|               | Ovary         | 288     | 20.4   | Colorectum  | 137    | 18.0 |
|               | Colorectum    | 186     | 13.2   | Ovary       | 106    | 13.9 |
|               | Lung          | 74      | 5.2    | Lung        | 41     | 5.4  |
|               | Kidney        | 62      | 4.4    | Leukemia    | 28     | 3.7  |
| Prostate      | Colorectum    | 1188    | 20.9   | Colorectum  | 963    | 23.7 |
|               | Bladder       | 1139    | 20.0   | Bladder     | 724    | 17.8 |
|               | Lung          | 811     | 14.3   | Lung        | 500    | 12.3 |
|               | Kidney        | 570     | 10.0   | Melanoma    | 240    | 5.9  |
|               | Stomach       | 337     | 5.9    | NHL         | 235    | 5.8  |
| Kidney        | Prostate      | 598     | 28.4   | Bladder     | 143    | 23.9 |
|               | Colorectum    | 285     | 13.5   | Prostate    | 143    | 23.9 |
|               | Bladder       | 278     | 13.2   | Colorectum  | 56     | 9.3  |
|               | Lung          | 193     | 9.2    | Lung        | 52     | 8.7  |
|               | Breast        | 138     | 6.6    | Breast      | 46     | 7.7  |
| Bladder       | Prostate      | 2037    | 55.1   | Prostate    | 844    | 45.4 |
|               | Lung          | 446     | 12.1   | Lung        | 212    | 11.4 |
|               | Colorectum    | 318     | 8.6    | Colorectum  | 174    | 9.4  |
|               | Kidney        | 258     | 7.0    | Kidney      | 153    | 8.2  |
|               | Stomach       | 84      | 2.3    | Breast      | 72     | 3.9  |
| Melanoma      | Prostate      | 224     | 18.6   | Prostate    | 272    | 29.3 |
|               | Breast        | 174     | 14.4   | Breast      | 145    | 15.6 |
|               | Colorectum    | 167     | 13.8   | Colorectum  | 114    | 12.3 |
|               | Lung          | 110     | 9.1    | Lung        | 58     | 6.3  |
|               | Kidney        | 85      | 7.0    | Bladder     | 45     | 4.8  |
| NHL           | Lung          | 166     | 14.8   | Prostate    | 138    | 20.3 |
|               | Colorectum    | 152     | 13.6   | Colorectum  | 90     | 13.3 |
|               | Prostate      | 148     | 13.2   | Lung        | 58     | 8.5  |
|               | Breast        | 96      | 8.6    | Leukemia    | 55     | 8.1  |
|               | Leukemia      | 81      | 7.2    | Breast      | 45     | 6.6  |

$^*_{r_s}$ P-value
ovary cancers. Breast cancer, ovary cancer, CRC, and lung cancers were the four SPCs after endometrial cancer. Bladder cancer was followed by the four SPCs including prostate cancer, lung cancer, CRC, and kidney cancer. Prostate cancer (18.6% vs. 29.3%), breast cancer (14.4% vs. 15.6%), CRC (13.8% vs. 12.3%), and lung cancer (9.1% vs. 6.3%) following melanoma were found for the two datasets.

Spearman’s rank correlation coefficients showed that there was a strong positive correlation based on the ranks of thirty possible SPCs after all selected first cancers between the two datasets. Spearman’s correlation coefficient ($r_s$) was 0.90 for CRC, 0.86 for lung cancer, 0.85 for breast cancer, 0.83 for endometrial cancer, 0.96 for prostate cancer, 0.72 for bladder cancer, 0.85 for melanoma, 0.91 for NHL, and 0.90 for leukemia. $P$ values for all these $r_s$ were less than 0.001 (Table 2).

Figures 1, 2 show percentage of all discordant SPCs combined following 10 common first cancers by sex in Germany and Sweden. The order of 10 common first cancers, ranked in descending incidence of the SPCs after the respective first cancers, was similar in the two populations, irrespective of the patients’ gender. For instance, male patients with bladder cancers had the highest incidence of the SPCs (11.5% vs. 13.0%), and those with lung cancers had the lowest incidence of the SPCs (2.3% vs. 2.3%) (Fig. 1). For female patients, the highest SPC incidence appeared after endometrial cancers (5.0% vs. 7.4%) and the lowest one appeared after lung cancer (1.8% vs. 2.1%) in the two datasets (Fig. 2).

**Discussion**

To our knowledge, this is the first comprehensive population-based comparison of SPCs in different populations. When comparing the ranking and proportion of the five most common SPCs after particular first primary cancers between the two populations, we found that there was a similar order of the five leading SPCs after most selected first primaries, especially for kidney cancer, NHL, and leukemia (Table 2). Furthermore, high positive correlations between the German and Swedish datasets were
observed based on the ranks of thirty possible SPCs after all selected first cancers (Table 2). Of course the high correlation is driven by the overall incidence of cancers, including SPCs but nevertheless the consistent findings in the two populations provide support for the existence of uniform etiological processes underlying SPCs.

An important question in discussing similarities in the occurrence of SPCs is the incidence of first primary cancers. According to Cancer Incidence in Five Continents IX (www.iarc.fr), the male incidence of all cancers (around year 2000, without skin cancer) was 261 in Sweden (per 100,000) compared with 332 in Saarland, 345 in Mecklenburg-Western Pomerania, 315 in Munster, and 291 in Hamburg (as examples of the German rates, provided by these cancer registries). The differences were largely explained by tobacco-related sites because the incidence in lung cancer was almost three times higher in German men compared with Swedes. CRC was also more common in Germany while the opposite was true for prostate cancer; however, even for these cancers the Swedish rates were approximately within the incidence range in Germany. For women, the incidence of all cancer in Sweden was between the individual rates for the German cancer registries, and this applied to practically all individual sites.

Major strengths of this study are its design of population-based comparison and its subanalysis by specific SPCs. Analysis of large cancer registries including the Swedish Cancer Registry has consistently shown an excess burden of all SPCs combined, that is, there is an increased risk to develop any SPC after a primary cancer [11–17]. However, the present analysis by specific SPCs showed a more thorough picture, in which the more detailed information may reveal a compelling clinical agenda. However, it is important to keep in mind that surveillance bias may contribute to an excess risk of SPCs. Chance findings are also possible but the consistent results for the two datasets should reduce such possibilities.

In this study, the correlation coefficients for SPCs after 10 common cancers other than bladder cancer ($r_s: 0.72$) were greater than 0.80, indicating strikingly consistent patterns for developing a specific SPC in the two populations. Additionally, the five most common SPCs after kidney cancer, NHL, or leukemia were totally identical between the two datasets, and those after CRC, lung cancer, breast cancer, endometrial cancer, bladder cancer, or melanoma was 80% identical (4/5). The present findings showed that prostate cancer was the most common SPC in male cancer survivors with CRC, kidney cancer, bladder cancer, melanoma, or leukemia in the two populations, and breast cancer was the most common one after endometrial cancer. Although the detection of these SPCs may often be affected by general population screening such as screening mammography and prostate-specific antigen screening, aggregate data on SPCs and the specific risk data may certainly guide surveillance protocols tailored to the SPCs in question and inform decisions about personalized medicine. Taken together, the above consistent findings in the two populations should facilitate early detection and treatment of SPC [18].

State-of-the-art investigations on SPCs should also cover genetic predisposition [19]. A recent genome-wide association study (GWAS) successfully explored the common genetic variations associated with susceptibility to SPCs [20]. This study was conducted in survivors of Hodgkin’s lymphoma treated with radiotherapy, and successfully identified a set of single nucleotide polymorphisms (SNPs) at chromosome 6p21 that were strongly associated with SPC risk. Such studies may shed light on the way for further investigations of the complex interactions between genetic and environmental factors involved in the development of SPC [21]. Heterogeneity among the SPCs, however, was substantial, pointing out the need for separate evaluations by specific first and second primary pairs to explore the etiology of SPCs [22]. A 2007 study showed a common genetic risk factor (Chr. 8q24 variants) for colorectal and prostate cancers [23]. The present study supported the association between these two cancers at a population level and through replications in the two populations. The associations between first and SPCs may reflect emerging research priorities into SPC. For instance, there has been inconsistent evidence of excess bladder cancer after prostate cancer [24–27]. A number of studies linked an increased risk of bladder cancer specifically to prostate cancer radiotherapy or smoking [28–30].

In summary, the consistent patterns of the SPCs in the German and the Swedish populations were striking. Results on SPCs provide guidance to surveillance and early intervention strategies which should be tailored to specific SPCs. Effective prevention of SPCs requires a better understanding of their causes.

**Acknowledgments**

Members of the GEKID Cancer Survival Working Group: Andrea Eberle, Sabine Luttmann (Cancer Registry of Bremen); Roland Stabenow (Cancer Registry of Berlin and the New Federal States); Joachim Kieschke, Eunice Sirri (Cancer Registry of Lower Saxony); Bernd Holleczek (Saarland Cancer Registry); Katharina Emrich (Cancer Registry of Rhineland-Palatinate); Hiltraud Kajüter, Volkmar Mattauch (Cancer Registry of North Rhine-Westphalia); Alexander Katalinic (Cancer Registry of Schleswig-Holstein); Karla Geiss, Martin Meyer (Cancer Registry of Bavaria); Stefan Hentschel, Alice Nennecke...
(Hamburg Cancer Registry); Klaus Kraywinkel (Robert Koch Institute, Berlin); Hermann Brenner, Adam Gondos, Lina Jansen (DKFZ).

**Conflict of Interest**

None declared.

**References**

1. Rheingold, S. R., A. I. Neugut, and A. T. Meadows. 2000. Secondary cancers: incidence, risk factors and management. Pp. 2399–2406 in R. C. Bast, D. W. Kufe, R. E. Pollock, R. R. Weichselbaum, J. F. Holland, and E. Frei, eds. Cancer medicine. B.C. Decker, Hamilton.

2. Hemminki, K., and P. Boffetta. 2006. Multiple primary cancers as clues to environmental and heritable causes of cancer and mechanisms of carcinogenesis. IARC Sci. Publ. 157:289–297.

3. Travis, L. B., C. S. Rabkin, L. M. Brown, J. M. Allan, B. P. Alter, C. B. Ambrosone, et al. 2006. Cancer survivorship–genetic susceptibility and second primary cancers: research strategies and recommendations. J. Natl. Cancer Inst. 98:15–25.

4. Alberts, D. S., 2006. Second cancers are killing us! Cancer Epidemiol. Biomarkers Prev. 15:2019.

5. Hemminki, K, J. Lorenzo Bermejo, and A Forsti. 2006. The management. Pp. 2399–2406 in R. C. Bast, D. W. Kufe, R. E. Pollock, R. R. Weichselbaum, J. F. Holland, and E. Frei, eds. Cancer medicine. B.C. Decker, Hamilton.

6. Nielsen, S. F., B. G. Nordestgaard, and S. E. Bojesen. 2012. Associations between first and second primary cancers: a population-based study. CMAJ 184:E57–E69.

7. Hayat, M. J., N. Howlader, M. E. Reichman, and B. K. Edwards. 2007. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program, Oncologist 12:20–37.

8. Shu, X., K. Sundquist, J. Sundquist, and K. Hemminki. 2012. Time trends in incidence, causes of death, and survival of cancer of unknown primary in Sweden. Eur. J. Cancer Prev. 21:281–288.

9. Hiripi, E., A. Gondos, K. Emrich, B. Holleczek, A. Katalinic, S. Luttmann, et al. 2012. Survival from common and rare cancers in Germany in the early 21st century. Ann. Oncol. 23:472–479.

10. Frodin, J. E., J. Ericsson, and L. Barlow. 1997. Multiple primary malignant tumors in a national cancer registry—reliability of reporting. Acta Oncol. 36:465–469.

11. Levi, F., L. Randimbison, V. C. Te, I. Rolland-Portal, S. Franceschi, and C. La Vecchia. 1993. Multiple primary cancers in the Vaud Cancer Registry, Switzerland, 1974–89. Br. J. Cancer 67:391–395.

12. Sankila, R., E. Pukkala, and L. Teppo. 1995. Risk of subsequent malignant neoplasms among 470,000 cancer patients in Finland, 1953–1991. Int. J. Cancer 60:464–470.

13. Travis, L. B., R. E. Curtis, H. Storm, P. Hall, E. Holowaty, F. E. Van Leeuwen, et al. 1997. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J. Natl. Cancer Inst. 89:1429–1439.

14. Dong, C., and K. Hemminki. 2001. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958–1996. Int. J. Cancer 93:155–161.

15. Mudie, N. Y., A. J. Swerdlow, C. D. Higgins, P. Smith, Z. Qiao, B. W. Hancock, et al. 2006. Risk of second malignancy after non-Hodgkin’s lymphoma: a British Cohort Study. J. Clin. Oncol. 24:1568–1574.

16. Youlden, D. R., and P. D. Baade. 2011. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer 11:83.

17. Shen, M., P. Boffetta, J. H. Olsen, A. Anderssen, K. Hemminki, E. Pukkala, et al. 2006. A pooled analysis of second primary pancreatic cancer. Am. J. Epidemiol. 163:502–511.

18. Vogel, V. G. 2006. Identifying and screening patients at risk of second cancers. Cancer Epidemiol. Biomarkers Prev. 15:2027–2032.

19. Krueger, H., D. McLean, and D. Williams, eds. 2008. The prevention of second primary cancers. Karger, Basel.

20. Best, T., D. Li, A. D. Skol, T. Kirchhoff, S. A. Jackson, Y. Yasui, et al. 2011. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin’s lymphoma. Nat. Med. 17:941–943.

21. Morton, L. M., and S. J. Chanock. 2011. A step toward slaying the hydra of second cancers. Nat. Med. 17:924–925.

22. Winget, M., and Y. Yasui. 2012. Variation in risk of second primary cancer. CMAJ 184:19–20.

23. Haiman, C. A., L. Le Marchand, J. Yamamato, D. O. Stram, X. Sheng, L. N. Kolonel, et al. 2007. A common genetic risk factor for colorectal and prostate cancer. Nat. Genet. 39:954–956.

24. Singh, A., Y. Kinoshita, P. M. Jr Rovito, S. Landas, J. Silberstein, I. Nsouli, et al. 2008. Higher than expected association of clinical prostate and bladder cancers. J. Urol. 179(Suppl. 5):S2–S5.

25. Kinoshita, Y., A. Singh, P. M. Rovito Jr., C. Y. Wang, R. C. Bast, D. W. Kufe, R. E. Pollock, R. R. Weichselbaum, J. F. Holland, and E. Frei, eds. 2008. The prevention of second primary cancers. Karger, Basel.

26. Kellen, E., M. P. Zeegers, M. Dirx, S. Houterman, M. P. Zeegers, M. Dirx, S. Houterman, et al. 2008. Higher than expected association of clinical prostate and bladder cancers. J. Urol. 179(Suppl. 5):S2–S5.

27. Goldstraw, M. A., H. Payne, and R. S. Kirby. 2006. What are the risks of second cancer formation after radiotherapy to the prostate? BJU Int. 98:489–491.

28. Neugut, A. I., H. Ahsan, E. Robinson, and R. D. Ennis. 1997. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer 79:1600–1604.
29. Boorjian, S., J. E. Cowan, B. R. Konety, J. DuChane, A. Tewari, P. R. Carroll, et al. 2007. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J. Urol. 177:883–887; discussion 7–8.

30. Chrouser, K., B. Leibovich, E. Bergstralh, H. Zincke, and M. Blute. 2008. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J. Urol. 179(Suppl. 5):S7–S11.